1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Morphine Sulfate Injection - preservative-free (Hospira, Inc.)

Trade Name: Not established
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical active used as opioid analgesic

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification
Reproductive Toxicity: Category 1B
Effects on or via lactation

Label Elements

Signal Word: Danger
Hazard Statements: H362 - May cause harm to breast-fed children
H360D - May damage the unborn child

Precautionary Statements:
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P263 - Avoid contact during pregnancy/while nursing
P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P308 + P313 - IF exposed or concerned: Get medical attention/advice
Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine Sulfate</td>
<td>64-31-3</td>
<td>200-582-8</td>
<td>Acute Tox. 4 (H302)</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Repr. 1B (H360D)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lact. (H362)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Muta. 2 (H341)</td>
<td></td>
</tr>
<tr>
<td>HYDROCHLORIC ACID</td>
<td>7647-01-0</td>
<td>231-595-7</td>
<td>Skin Corr.1B (H314)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>STOT SE 3 (H335)</td>
<td></td>
</tr>
<tr>
<td>Citric acid, anhydrous</td>
<td>77-92-9</td>
<td>201-069-1</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>215-185-5</td>
<td>Skin Corr.1A (H314)</td>
<td>**</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>Not Listed</td>
<td></td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary
** to adjust pH
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free
(Hospira, Inc.)
Revision date: 11-Jun-2018
Version: 1.3

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

Advice for Fire-Fighters
During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of the spill if it is safe to do so. Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit: 2 ppm
Australia PEAK 5 ppm
Austria OEL - MAKs 5 ppm
Belgium OEL - TWA 5 ppm
Bulgaria OEL - TWA 5 ppm
Cyprus OEL - TWA 5 ppm
Czech Republic OEL - TWA 8 mg/m³
Estonia OEL - TWA 5 ppm
Germany - TRGS 900 - TWAs 2 ppm
Germany (DFG) - MAK 2 ppm
Greece OEL - TWA 5 ppm
Hungary OEL - TWA 8 mg/m³
Ireland OEL - TWAs 5 ppm
Italy OEL - TWA 5 ppm
Japan - OELs - Ceilings 2 ppm
Latvia OEL - TWA 5 ppm
Lithuania OEL - TWA 5 ppm
Luxembourg OEL - TWA 5 ppm
Malta OEL - TWA 5 ppm
Netherlands OEL - TWA 8 mg/m³
Poland OEL - TWA 5 mg/m³
Portugal OEL - TWA 5 ppm
Romania OEL - TWA 5 ppm
Slovakia OEL - TWA 5 ppm
Slovenia OEL - TWA 5 ppm
Spain OEL - TWA 5 ppm

Material Name: Morphine Sulfate Injection - preservative-free (Hospira, Inc.)
Revision date: 11-Jun-2018
Version: 1.3
### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Material Name: Morphine Sulfate Injection - preservative-free (Hospira, Inc.)</th>
<th>Page 5 of 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision date: 11-Jun-2018</td>
<td>Version: 1.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Country/Region</th>
<th>OEL - TWAs</th>
<th>OEL - MAKs</th>
<th>OEL - TWA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Belgium</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>1 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Croatia</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Denmark</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Estonia</td>
<td>1 mg/m³</td>
<td></td>
<td>1 mg/m³</td>
</tr>
<tr>
<td>Finland</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>France</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Germany</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Greece</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Hungary</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Italy</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Japan</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Latvia</td>
<td>0.5 mg/m³</td>
<td></td>
<td>0.5 mg/m³</td>
</tr>
<tr>
<td>Lithuania</td>
<td>5 mg/m³</td>
<td></td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>5 mg/m³</td>
<td></td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Malaysia</td>
<td>5 mg/m³</td>
<td></td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Netherlands</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>New Zealand</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Norway</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Poland</td>
<td>0.5 mg/m³</td>
<td></td>
<td>0.5 mg/m³</td>
</tr>
<tr>
<td>Portugal</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Romania</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Russia</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Slovakia</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Slovenia</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Spain</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Sweden</td>
<td>1 mg/m³</td>
<td></td>
<td>1 mg/m³</td>
</tr>
<tr>
<td>Switzerland</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Taiwan</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Thailand</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Turkey</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>United States</td>
<td>1 mg/m³</td>
<td></td>
<td>1 mg/m³</td>
</tr>
<tr>
<td>Venezuela</td>
<td>2 mg/m³</td>
<td></td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Vietnam</td>
<td>5 mg/m³</td>
<td></td>
<td>5 mg/m³</td>
</tr>
</tbody>
</table>

#### Sodium hydroxide

- **ACGIH Ceiling Threshold Limit:** 2 mg/m³

#### Sodium chloride

- **OSHA - Final PELS - TWAs:** 2 mg/m³

#### Morphine Sulfate

- **Pfizer Occupational Exposure Band (OEB):** OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

#### Sodium chloride

- **Pfizer Occupational Exposure Band (OEB):** OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

#### Exposure Controls

**Engineering Controls:**

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment:**

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

**Hands:**

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

**Eyes:**

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

**Skin:**

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical State</td>
<td>Solution</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available.</td>
</tr>
<tr>
<td>Molecular Formula</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Water Solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting/Freezing Point (°C)</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling Point (°C)</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition Coefficient (Method, pH, Endpoint, Value)</td>
<td>No data available</td>
</tr>
<tr>
<td>Water for injection</td>
<td>No data available</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>No data available</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>No data available</td>
</tr>
<tr>
<td>HYDROCHLORIC ACID</td>
<td>No data available</td>
</tr>
<tr>
<td>Citric acid, anhydrous</td>
<td>No data available</td>
</tr>
<tr>
<td>Sodium citrate, dihydrate</td>
<td>No data available</td>
</tr>
<tr>
<td>Morphine Sulfate</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition Temperature (°C)</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation Rate (Gram/s)</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Pressure (kPa)</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Density (g/ml)</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability</td>
<td>No data available</td>
</tr>
<tr>
<td>Autoignition Temperature (Solid) (°C)</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (Solids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash Point (Liquid) (°C)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper Explosive Limits (Liquid) (% by Vol.)</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower Explosive Limits (Liquid) (% by Vol.)</td>
<td>No data available</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
10. STABILITY AND REACTIVITY

| Oxidizing Properties: | No data available |
| Conditions to Avoid: | Fine particles (such as dust and mists) may fuel fires/explosions. |
| Incompatible Materials: | As a precautionary measure, keep away from strong oxidizers |
| Hazardous Decomposition Products: | No data available |

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: May be harmful if swallowed. May cause eye irritation (based on components).
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the developing fetus.
Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including dry mouth, drowsiness, headache, dizziness, nausea, vomiting, weakness, anxiety, blurred vision and dilated pupils. Cases of overdosage may also lead to respiratory depression, hypotension, coma, convulsions, cardiac arrhythmia, and tachycardia.

Acute Toxicity: (Species, Route, End Point, Dose)

**Sodium chloride**
- Rat Oral LD50 3000 mg/kg
- Mouse Oral LD50 4000 mg/kg

**Sodium hydroxide**
- Mouse IP LD50 40 mg/kg

**HYDROCHLORIC ACID**
- Rat Oral LD50 238-277 mg/kg

**Citric acid, anhydrous**
- Rat Oral LD50 3000 mg/kg

**Morphine Sulfate**
- Rat Oral LD50 461 mg/kg
- Rat Para-periosteal LD50 70mg/kg
- Rat Intraperitoneal LD50 235mg/kg
- Mouse Oral LD50 600mg/kg
- Mouse Intravenous LD50 156mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

**Sodium chloride**
- Eye Irritation Rabbit Moderate
- Skin Irritation Rabbit Mild

**Sodium hydroxide**
- Eye Irritation Rabbit Severe
11. TOXICOLOGICAL INFORMATION

**Skin Irritation**  Rabbit  Severe

**Citric acid, anhydrous**
Eye Irritation  Rabbit  Severe
Skin Irritation  Rabbit  Mild

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

**Morphine Sulfate**
- 18 Week(s)  Rat  Oral  60 g/kg  LOAEL  Lungs
- 15 Day(s)  Rat  Subcutaneous  3144 mg/kg  LOAEL  Kidney, Ureter, Bladder
- 9 Week(s)  Rat  Subcutaneous  3150 mg/kg  LOAEL

**Embryo / Fetal Development**

**Morphine Sulfate**
- Mouse  Subcutaneous  0.15 mg/kg  LOAEL  Teratogenic
- Hamster  Subcutaneous  35 mg/kg  LOAEL  Teratogenic
- Mouse  Oral  200 mg/kg  LOAEL  Teratogenic
- Rat  Subcutaneous  35 mg/kg  LOAEL  Fetotoxicity

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

**HYDROCHLORIC ACID**
- Bacterial Mutagenicity (Ames)  *Salmonella*  Negative
- In Vivo Micronucleus  Rat  Negative

**Morphine Sulfate**
- In Vivo Micronucleus  Mouse  Positive
- In Vivo Chromosome Aberration  Mouse Lymphocytes  Positive
- In Vitro Direct DNA Damage  Human Lymphocytes  Positive
- In Vitro Chromosome Aberration  Mouse  Negative
- Dominant Lethal Assay  Drosophila  Negative

**Carcinogen Status:**  See below

**HYDROCHLORIC ACID**
- IARC:  Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

**Environmental Overview:**  Environmental properties of the formulation have not been thoroughly investigated. Releases to the environment should be avoided.

**Toxicity:**  No data available

**Persistence and Degradability:**  No data available
Bio-accumulative Potential:  No data available
Mobility in Soil:  No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:  Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Morphine Sulfate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- U.S. Drug Enforcement Administration: Schedule II
- Australia (AICS): Present
- EU EINECS/ELINCS List: 200-582-8

Water for injection
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: 231-791-2

HYDROCHLORIC ACID
Material Name: Morphine Sulfate Injection - preservative-free
(Hospira, Inc.)
Revision date: 11-Jun-2018
Version: 1.3

15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Substance</th>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>California Prop 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium hydroxide</td>
<td>1.0 %</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>215-185-5</td>
</tr>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>231-598-3</td>
</tr>
<tr>
<td>California Prop 65</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>201-069-1</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>231-595-7</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>231-595-7</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Citric acid, anhydrous

<table>
<thead>
<tr>
<th>Substance</th>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>California Prop 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium citrate, dihydrate</td>
<td></td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>California Prop 65</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3
SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free (Hospira, Inc.)
Revision date: 11-Jun-2018

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children
Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources:
Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision:
Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date:
11-Jun-2018

Prepared by:
Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet